Although methotrexate is the main therapy for rheumatoid arthritis, surprisingly little is known about the optimal route of administration; bioavailability of methotrexate has been shown to vary accordingly. In terms of delaying a switch to biologic therapy, is the subcutaneous route superior to oral methotrexate therapy?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Handlungsempfehlung zur Therapieumstellung von Immunsuppressiva auf Dupilumab bei Patienten mit atopischer Dermatitis
Der Hautarzt Open Access 11 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
17 September 2014
In the original version of this article published online the competing interest statement for S.A. was missing. This error has now been corrected in the HTML and PDF versions of the article.
References
Curtis, J. R. et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. (Hoboken) http:dx.doi.org/10.1002/acr.22383.
Visser, K. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann. Rheum. Dis. 68, 1086–1089 (2009).
Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 625–639 (2012).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492–509 (2014).
Hoekstra, M. et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J. Rheumatol. 31, 645–648 (2004).
Schiff, M. H., Jaffe, J. S. & Freundlich, B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann. Rheum. Dis. 73, 1549–1551 (2014).
Bakker, M. F. et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann. Rheum. Dis. 69, 1849–1852 (2010).
Braun J. et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 58, 73–81 (2008).
Hazlewood, G. et al. Subcutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration for the initial treatment of patients with early rheumatoid arthritis [abstract]. Arthritis Rheum. 65 (Suppl. 10), 627 (2013).
Fitzpatrick, R., Scott, D. G. & Keary, I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have had an insufficient response or intolerance to oral methotrexate. Clin. Rheumatol. 32, 1605–1612 (2013).
Acknowledgements
The authors acknowledge the excellent secretarial assistance of S. Gillard.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.C.K. declares that he is a consultant for Antares Pharma. S.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Alsaeedi, S., Keystone, E. Oral or subcutaneous methotrexate for rheumatoid arthritis?. Nat Rev Rheumatol 10, 578–579 (2014). https://doi.org/10.1038/nrrheum.2014.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.129
This article is cited by
-
Handlungsempfehlung zur Therapieumstellung von Immunsuppressiva auf Dupilumab bei Patienten mit atopischer Dermatitis
Der Hautarzt (2021)
-
Treatment of rheumatoid arthritis (RA) in India—how and by whom: results from a speciality clinic—use of low-dose methotrexate (MTX) was inexplicably suboptimal
Clinical Rheumatology (2016)